Five genetic variants associated with prostate cancer
Gartner, C.E.; Barendregt, J.J.; Hall, W.D.
New England Journal of Medicine 358(25): 2738-2739; Author Reply 2741
2008
ISSN/ISBN: 0028-4793 PMID: 18572445 Document Number: 615962
Document emailed within 1 workday
Related Documents
Kucukgergin, C.; Gokpinar, M.; Sanli, O.; Tefik, T.; Oktar, T.; Seckin, S. 2011: Association between genetic variants in glutathione peroxidase 1 (GPx1) gene, GPx activity and the risk of prostate cancer Minerva Urologica e Nefrologica 63(3): 183-190Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Romanenko, A.M.; Vorob'eva, L.R. 1995: Various immunohistochemical markers of precancer and variants of prostate cancer Arkhiv Patologii 57(4): 38-41
Woodson, A.H. 2019: Genetic counseling considerations for men with prostate cancer Canadian Journal of Urology 26(5 Suppl 2: 40-41
Ross, R.K.; Pike, M.C.; Coetzee, G.A.; Reichardt, J.K.; Yu, M.C.; Feigelson, H.; Stanczyk, F.Z.; Kolonel, L.N.; Henderson, B.E. 1998: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility Cancer Research 58(20): 4497-4504
Singh, H.; Sachan, R.; Goel, H.; Mittal, B. 2008: Genetic variants of interleukin-1RN and interleukin-1beta genes and risk of cervical cancer Bjog: An International Journal of Obstetrics and Gynaecology 115(5): 633-638
Reynolds, T. 2003: Study seeks to clarify genetic basis of prostate cancer in African Americans Journal of the National Cancer Institute 95(18): 1356-1357
Wu, Y.-J.; Liang, C.-H.; Zhou, F.-J.; Gao, X.; Chen, L.-W.; Liu, Q. 2009: A case-control study of environmental and genetic factors and prostate cancer in Guangdong Zhonghua Yu Fang Yi Xue Za Zhi 43(7): 581-585
Bright, R.K.; Vocke, C.D.; Emmert-Buck, M.R.; Duray, P.H.; Solomon, D.; Fetsch, P.; Rhim, J.S.; Linehan, W.M.; Topalian, S.L. 1997: Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens Cancer Research 57(5): 995-1002
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Rhim, J.S. 2003: Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro prostate cell models Drugs of Today 39(11): 837-847
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Alberti, C. 2016: Prostate cancer cell both microRNA aberrant expression-mediated autophagy and radiation therapy resistance with short cross-reference to epigenetic/genetic mechanism implications European Review for Medical and Pharmacological Sciences 20(6): 1001-1002
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001